PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board.
RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
Dr. Dritschilo is a renowned educator, inventor, translational scientist, and business executive.
Dr. Dritschilo is the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings, Inc. Formerly, as an educator and translational scientist, he was employed at the Georgetown University and the MedStar Georgetown University Hospital as a radiation oncologist and chairman of the Department of Radiation Medicine. Over a 40+ year career, he has provided clinical services to thousands of patients presenting with cancers of the breast, prostate, and the central nervous system. As a translational scientist, Dr. Dritschilo has focused his research on sensitizing cancers to ionizing radiation. He is a leader in the development of antisense oligonucleotides and small molecules directed at targets for radiation sensitization. He has also served as Medical Director of Georgetown University Hospital from 1994 to 1997, and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has been a member of the Boards of Directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Research Institute. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a BS degree in Chemical Engineering from the University of Pennsylvania, his medical degree from the College of Medicine of New Jersey, and residency training from the Harvard Joint Center for Radiation Therapy.
“I look forward to working with the Retinalgenix team of clinicians and scientists to address the need for biomarker technology for guiding diagnosis and management of systemic diseases that may be reflected in the eye,” said Dr. Dritschilo.
In concert with its Pharmaco-Genetic Mapping™ software, the Company is developing a high-resolution 24/7 real-time home and remote monitoring system to assist both physicians and patients. The use of the system does not require dilation of the pupil. The combined technologies are intended to prevent blindness through the early detection and treatment of ocular diseases and systemic diseases including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.
The company is making progress in conducting pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) through Avania, its contract research organization (CRO). Additionally, the company is developing plans to conduct a future study of Alzheimer’s/Dementia complex as part of the DNA/RNA GPS™ initiative.
RetinalGeniX has also filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study that is intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD.
Jerry Katzman MD, Chairman, President, and CEO of RetinalGeniX Technologies Inc., said, “We are thrilled to welcome Dr. Dritschilo as a Senior Consultant to assist with our Pharmaco-Genetic anti-VEGF study and the suitability of ocular injection therapy to patients prior to its use. Dr. Anatoly will oversee many aspects of the study with Dr. Larry Perich and Fred Chasalow PhD on different aspects of their work. Dr. Dritschilo’s accomplishments are truly remarkable. We are looking forward to working together to advance our Anti-VEGF study for the benefit of patients worldwide.”
About RetinalGeniX™
RetinalGeniX is an ophthalmic research and development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies intended to prevent blindness through the early detection and treatment of ocular diseases and also to detect initial physiological changes that could indicate possible future systemic disease including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding Dr. Dritschilo working with the Retinalgenix team of clinicians and scientists to address the need for biomarker technology for guiding diagnosis and management of systemic diseases that may be reflected in the eye, the Company developing a high-resolution 24/7 real-time home and remote monitoring system to assist both physicians and patients, preventing blindness through the early detection and treatment of ocular diseases and systemic diseases, developing plans to conduct a future study of Alzheimer’s/Dementia complex as part of the DNA/RNA GPS™ initiative, launching a 390-patient clinical study that is intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD and advancing the Company’s Anti-VEGF study for the benefit of patients worldwide. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the contribution of Dr. Dritschilo to the Company, the Company’s ability to successfully complete research and further development and commercialization of Company drug candidates, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s drug candidates, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact
RetinalGeniX Technologies, Inc.
Jerry Katzman, MD, CEO
jkatzman@retinalgenix.com
+1 (415) 578-9761
www.retinalgenix.com
